Key Highlights
The US approval of Jynarque added the much-needed push to the ADPKD treatment market.In the coming years, Bardoxolone methyl is expected to be an effective therapy for ADPKD treatment.The current ADPKD treatment only aims to delay the disease progression rather than completely cure the disease, which leads to an unmet need for ADPKD management.
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent type of PKD. ADPKD affects approximately 1 in every 400 to 1,000 individuals and is the most common kidney disease passes down via families. According to NAMCS (National Ambulatory Medical Care Survey), which was conducted by the Cent...
